AGIO:NSD-Agios Pharm (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 48.05

Change

-0.98 (-2.00)%

Market Cap

USD 2.79B

Volume

1.79M

Analyst Target

USD 65.45
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 88 Sidney Street, Cambridge, MA, United States, 02139

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.81 (+0.85%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+1.39 (+0.30%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

+1.84 (+0.67%)

USD 35.01B
ARGX argenx NV ADR

-24.43 (-4.45%)

USD 32.83B
MRNA Moderna Inc

+0.29 (+0.46%)

USD 25.25B
BGNE BeiGene Ltd

+5.81 (+2.81%)

USD 22.45B
SMMT Summit Therapeutics PLC

+0.17 (+0.75%)

USD 17.92B
RPRX Royalty Pharma Plc

+0.54 (+1.95%)

USD 16.34B
UTHR United Therapeutics Corporatio..

-1.79 (-0.50%)

USD 15.71B
PCVX Vaxcyte Inc

-2.02 (-1.78%)

USD 14.50B

ETFs Containing AGIO

WDNA:LSE WisdomTree BioRevolution .. 2.44 % 0.00 %

+0.10 (+0%)

N/A
WDNA 2.36 % 0.00 %

N/A

N/A
WBIO:LSE WisdomTree BioRevolution .. 2.35 % 0.00 %

+1.80 (+0%)

USD 3.87M
WRNA:XETRA WisdomTree BioRevolution .. 2.28 % 0.00 %

+0.07 (+0%)

USD 2.77M
ETHO Amplify ETF Trust 0.53 % 0.45 %

+0.66 (+0%)

USD 0.18B
AVSC American Century ETF Trus.. 0.34 % 0.00 %

+0.57 (+0%)

USD 1.34B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 115.76% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 115.76% 92% A 95% A
Trailing 12 Months  
Capital Gain 93.98% 86% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.98% 86% B+ 92% A
Trailing 5 Years  
Capital Gain 39.48% 76% C+ 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.48% 76% C+ 65% D
Average Annual (5 Year Horizon)  
Capital Gain -1.64% 52% F 39% F
Dividend Return -1.64% 52% F 35% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.59% 78% C+ 54% F
Risk Adjusted Return -4.74% 50% F 36% F
Market Capitalization 2.79B 91% A- 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector